Pipeline

Talem has leveraged its expertise in antibody discovery and development to establish a sustainable pipeline of next-generation antibody therapeutics for multiple disease indications. This is achieved by combining IPA’s innovative and proprietary technologies with Talem’s preclinical expertise to develop medically relevant antibody therapeutics in a clinically relevant market.

Each Talem Internal Program is available for licensing and partnering. For more information on Talem assets or for licensing and partnering opportunities please contact bd@talemtherapeutics.com

Talem Pipeline

To learn more about Talem Programs download the Talem Pipeline Overview. To sign up for late-breaking pipeline advancements send us an email here.

TATX-03 "PolyTope®" - Preclinical IND Enabling

One of Talem’s most advanced development programs, TATX-03 (anti-SARS-CoV-2 PolyTope® monoclonal antibody cocktail), is a rationally designed, fully human, 4-antibody cocktail containing potently neutralizing antibodies against non-overlapping epitopes on SARS-CoV-2. Talem’s SARS-CoV-2 PolyTope® therapy is designed to reduce mutagenic escape risk with an emphasis on efficacy for every patient, variant, and strain of SARS-CoV-2, and has been developed with the goal of sustainable efficacy as the virus evolves, combining broadly characterized, neutralizing and synergistic antibodies that exhibit diverse epitope coverage.

Target: SARS-CoV-2 and its variants

Type of Molecule: Biologic, multi-antibody cocktail

Status: IND-Enabling

Visit The PolyTope TATX-03 for more information.

TATX-112 - Lead Candidate Selection

TATX-112 is a diverse panel of human and chicken-derived monoclonal antibodies against TrkB. TATX-112 antibodies are being investigated to treat different cancer types by different approaches, including antibody drug conjugate-based (ADC) strategies, bispecific approaches and therapeutic options focusing on functional interference with TrkB signaling inducing tumor regression. Separately, TATX-112 anti-TrkB agonist antibodies are being investigated to treat neuro-related disorders resulting from disturbed TrkB signaling (Alzheimer’s, Auditory System, and Ophthalmology).

Target: TrkB

Type of Molecule: Biologic – monoclonal and bispecific

Indications: Oncology and Neuro-related Disorders

Status: Lead Candidate Selection (per therapeutic approach

TATX-21 - Lead Candidate Selection

TATX-21 is a diverse panel of rabbit-derived monoclonal antibodies against ALK1. Anti-ALK1 antibodies are being investigated to block LDL-mediated transcytosis to treat cardiovascular disease (Atherosclerosis cardiovascular disease). In addition, TATX-21 anti-ALK1 with proven anti-angiogenic effects will be investigated to treat solid tumors. Anti-ALK1 agonists are being investigated to treat diabetic retinopathy.

Target: ALK1

Type of Molecule: Biologic – monoclonal

Indications: Cardiovascular Disease, Oncology, and Diabetic Retinopathy 

Status: Lead Candidate Selection (per therapeutic approach)

Target: Not Disclosed 

Type of Molecule: Biologic – monoclonal 

Indications: Oncology, Auto-Immune Disease, and Inflammation 

Mechanism of Actions: CDC, ADCC, and ADCP 

Status: Lead Candidate Selection (per therapeutic approach) 

Target: Not Disclosed 

Type of Molecule: Biologic – monoclonal 

Indications: Oncology, Auto-Immune Disease, and Inflammation 

Mechanism of Actions: CDC, ADCC, and ADCP 

Status: Lead Candidate Selection (per therapeutic approach) 

Target: Not Disclosed 

Type of Molecule: Biologic – monoclonal 

Indications: Solid Tumor and Acute Myeloid Leukemia 

Mechanism of Actions: CAR-T, ADC, CDC, ADCC, ADCP 

Status: Discovery Stage (per therapeutic approach) 

Target: Not Disclosed 

Type of Molecule: Biologic – monoclonal 

Indications: Solid Tumors and Pgp+ Tumors (multiple drug resistant) 

Mechanism of Actions: Blocking (pH restoration) and overcome multiple drug resistance 

Status: Discovery Stage (per therapeutic approach) 

Target: Not Disclosed 

Type of Molecule: Biologic – bispecific 

Indications: Immuno-Oncology 

Mechanism of Actions: T-cell activation facilitating tumor cell destruction (next generation bispecific) 

Status: Discovery Stage  

Disclaimer

This information was factually accurate on the date it was published. Talem assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Talem pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Talem’s business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Talem Therapeutics LLC regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels. 

In particular, management’s expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the ImmunoPrecise Antibodies Ltd. Group’s ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in ImmunoPrecise Antibodies’ current Form 40-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.